

CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF CONDENSED AZACYCLES (CANNABINOID RECEPTOR MODULATORS)

ABSTRACT

5 The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-
1a,2,5.5a-tetrahydro- 1 H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)- 1 -
hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions
thereof that modulate the activity of the cannabinoid CB₂ receptor and are therefore useful in t
treatment of CB₂ receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia;
10 allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis;
multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions CNS
inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation
associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft
rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel
15 disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration;
cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced
damage; dementia; amyotrophic lateral sclerosis; and Parkinson's disease.

[Fig. 1]